clobetasol propionate + etanercept

Clobetasol propionate + etanercept is a combination therapy consisting of a potent topical corticosteroid (clobetasol propionate) and a biologic tumor necrosis factor (TNF) inhibitor (etanercept). This combination has been studied for the treatment of moderate to severe plaque psoriasis. Clobetasol propionate acts by binding to the glucocorticoid receptor, leading to anti-inflammatory and immunosuppressive effects in the skin. Etanercept is a dimeric fusion protein that binds TNF-alpha, inhibiting its pro-inflammatory activity systemically. Clinical studies have shown that adding clobetasol propionate to etanercept increases efficacy in achieving significant improvement in psoriasis severity compared with etanercept alone, without increasing adverse events[1][3][9]. Both agents are approved individually for use in plaque psoriasis and other inflammatory conditions.